AG Mednet Names Michael Svinte Chief Commercial Officer, Will Grow Commercial Team Globally
AG Mednet, a technology company with a mission to speed medical innovation from testing to patients, has named Mike Svinte as chief commercial officer. In his new position, Mike will significantly expand AG Mednet’s commercial footprint, and continue to advance the company beyond its strong 2020 growth which saw more than 25 percent revenue growth led by more than 70 percent increase in usage of its flagship SaaS product, Judi, for clinical trial endpoint adjudication, DSMB, central eligibility and imaging workflows. Mike will lead sales, marketing, channel partnerships and strategic relationships with sponsors in biotech, pharma and medical devices, as well as manage existing relationships with the top 10 CROs. AG Mednet is currently growing its commercial team across the U.S. as well as in Europe and APAC.
Mike has held global leadership positions with responsibility for driving innovation and delivering client value at the intersection of healthcare, life sciences and disruptive technologies. A global executive at IBM for nearly 20 years, Svinte had leadership responsibilities for a multibillion-dollar healthcare and life sciences business unit. He led the creation and execution of IBM’s healthcare initiatives, including serving on the leadership team for the IBM Watson Health launch, led worldwide business development for IBM Life Sciences, and shaped IBM’s growth strategy and investments for its Information-Based Medicine startup health venture. He held executive leadership positions in IBM Global Services and IBM corporate headquarters. Mike also led commercial teams as SVP for Medidata and Chief Commercial Officer for SAP Health. He began his career at Procter & Gamble in brand management and sales leadership. He holds a Bachelor of Business Administration degree from the University of Michigan School of Business.
“Demand for clinical trial process management and transformation as well as a need to develop and test new drugs and devices at a scale never before seen in the industry creates opportunity for AG Mednet to further disrupt clinical trial technology,” said Abraham Gutman, founder and CEO of AG Mednet. “With a storied career at global organizations and within the healthcare, life sciences and clinical trial industries, Mike is the ideal professional to grow our commercial teams worldwide and to deepen our partnerships with CROs, sponsors and other major clinical trial partners. I’m excited for 2021 and beyond, and to see AG Mednet grow its global footprint under Mike’s leadership.”